Formation of Pseudomonas aeruginosa inhibition zone during tobramycin disk diffusion is due to transition from planktonic to biofilm mode of growth

Autor: Thomas Bjarnsholt, Kaj-Åge Henneberg, Oana Ciofu, Ulla Johansen, Camilla Stavnsbjerg, Hengshuang Wang, Thomas Sams, Niels Høiby

Publikováno v: Høiby, N, Henneberg, K Å, Wang, H, Stavnsbjerg, C, Bjarnsholt, T, Ciofu, O, Johansen, U R & Sams, T 2019, ' Formation of Pseudomonas aeruginosa inhibition zone during tobramycin disk diffusion is due to transition from planktonic to biofilm mode of growth ', International Journal of Antimicrobial Agents, vol. 53, no. 5, pp. 564-573 . https://doi.org/10.1016/j.ijantimicag.2018.12.015
Høiby, N, Henneberg, K-Å, Wang, H, Stavnsbjerg, C, Bjarnsholt, T, Ciofu, O, Johansen, U R & Sams, T 2019, ' Formation of Pseudomonas aeruginosa inhibition zone during Tobramycin disk diffusion is due to a transition from planktonic to biofilm mode of growth ', International Journal of Antimicrobial Agents, vol. 53, no. 5, pp. 564-573 . https://doi.org/10.1016/j.ijantimicag.2018.12.015

Pseudomonas aeruginosa PAO1 (tobramycin MIC = 0.064 µg/mL) was used to perform agar diffusion tests employing tobramycin-containing tablets. Bacterial growth and formation of inhibition zones were studied by stereomicroscopy and by blotting with mic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb45f83b0853f44f39a5a4eacb72ffa8
https://doi.org/10.1016/j.ijantimicag.2018.12.015

P044 Azithromycin resistance develops fast in P. aeruginosa but has no negative impact on lung function development in CF patients with chronic infection

Autor: Lars Jelsbak, O. Arge, Oana Ciofu, Marianne Skov, Tanja Pressler, Niels Høiby, C.R. Hansen, Ulla Johansen

Publikováno v: Journal of Cystic Fibrosis. 17:S71

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::991dc865846bed8e7805005c83fcbce3
https://doi.org/10.1016/s1569-1993(18)30341-2

The microorganisms in chronically infected end-stage and non-end-stage cystic fibrosis patients

Autor: Vibeke Børsholt Rudkjøbing, Michael Givskov, Niels Høiby, Thomas Bjarnsholt, Trine Rolighed Thomsen, Morten Alhede, Ulla Johansen, Kasper Nørskov Kragh, Per Halkjær Nielsen

Publikováno v: Rudkjøbing, V B, Thomsen, T R, Alhede, M, Kragh, K N, Nielsen, P H, Johansen, U R, Givskov, M, Høiby, N & Bjarnsholt, T 2012, ' The microorganisms in chronically infected end-stage and non-end-stage cystic fibrosis patients ', F E M S Immunology and Medical Microbiology, vol. 65, no. 2, pp. 236-244 . https://doi.org/10.1111/j.1574-695X.2011.00925.x

Patients suffering from cystic fibrosis (CF) develop chronic lung infections because of highly viscous mucus, where bacteria can form biofilms. In this study, we investigated the microorganisms present in the lungs of end-stage and non-end-stage pati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2720c01d43d6a5c6890c1ea2427b0b8
https://vbn.aau.dk/da/publications/b12367fe-575e-4375-b3ae-c149918f710c

Methods to Classify Bacterial Pathogens in Cystic Fibrosis

Autor: Niels Høiby, Thomas Bjarnsholt, Ulla Johansen, Xiaohui Chen Nielsen, Lena Nørgaard

Publikováno v: Methods in Molecular Biology ISBN: 9781617791192

Many bacteria can be detected in CF sputum, pathogenic and commensal. Modified Koch's criteria for identification of established and emerging CF pathogens are therefore described. Methods are described to isolate bacteria and to detect bacterial biof

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::97f79176e59711262bd2ee6a2a9a5e59
https://doi.org/10.1007/978-1-61779-120-8_9

Association between CYP3A enzyme activity and ciprofloxacin and clarithromycin pharmacokinetics in patients with cystic fibrosis

Autor: G. Jürgens, Xiaohui Chen Nielsen, Niels Høiby, Kim Dalhoff, C.R. Hansen, Tanja Pressler, Ulla Johansen, A.G. Jensen

Publikováno v: Journal of Cystic Fibrosis. 8

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::679d6fb83d1d61ef99643e61a4caae6a